|Videos|April 22, 2017

What is an Effective Stewardship Intervention for Penicillin-Related Allergies?

Emily Heil, PharmD, BCPS-AQ ID, assistant professor at the University of Maryland School of Pharmacy, shares an effective stewardship intervention for ruling out if someone is allergic to penicillin.

Emily Heil, PharmD, BCPS-AQ ID, assistant professor at the University of Maryland School of Pharmacy, shares an effective stewardship intervention for ruling out if someone is allergic to penicillin.

Interview Transcript (slightly modified for readability)

“Penicillin-related allergies and the antibodies that mediate those allergies can actually disappear over time. [In] up to 80% of patients that reported a penicillin allergy as a child over [about] a 10-year period, you can actually see a lot of those antibodies go away. So, just because a patient had an allergy in the past to an antibiotic, doesn’t mean that they still do, and that’s why something like penicillin skin testing to rule out a current allergy can be an effective stewardship intervention.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.